Abstract
Prognostic value of serum phosphoglycerate dehydrogenase and glycine levels in breast cancer
- Medical Chemistry Department, College of Medicine, University of AL-Qadisiyah, Al- Diywaniyah, Iraq
Introduction
Breast cancer (BC) is the most frequent cancer in women and is a serious worldwide health issue. Phosphoglycerate dehydrogenase (PHGDH) is an enzyme that catalyses the first steps in the serine biosynthetic pathways downstream of glycolysis. Phosphoglycerate and glycine are produced by a series of enzymatic processes from the glycolysis intermediate 3-phosphoglycerate. The aim of the study was to indicate the levels of PHGDH and glycine in patients with breast cancer.
Material and methods
The study was performed from December 2022 to March 2023. The total number of samples was 135 samples – 65 samples were collected from women with breast cancer, and 70 samples were from healthy women as a control group. Blood samples (5 ml) were obtained from all study group members. The complete blood count (CBC) neutrophils/lymphocytes, and haemoglobin ratio analysis was done on a CBC haematology analyser (Sysmex, Japan). Serum PHGDH and glycine were measure by enzyme-linked immunosorbent assay.
Results
The study findings revealed a significant increase in the neutrophil/lymphocytes ratio and a decrease in PHGDH level in patients with BC compare to controls (p < 0.01), while the serum glycine level showed a significant increase in patients with BC compare to the control group (p < 0.01).
Conclusions
Reduced PHGDH level and high glycine concentration in patients with BC could act as a prognostic factor in cancer development.
Keywords
breast cancer, PHGDH, glycine, serine synthesis pathway
Coverage in
Indexed in
Integrated with
Editorial Policies
